Antares Pharma, Inc. (NASDAQ:ATRS) has been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $3.84.

A number of equities research analysts recently weighed in on ATRS shares. HC Wainwright set a $5.00 price objective on shares of Antares Pharma and gave the company a “buy” rating in a report on Friday, October 13th. BidaskClub upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Piper Jaffray Companies set a $3.00 price objective on shares of Antares Pharma and gave the company a “buy” rating in a report on Monday, October 23rd. Finally, ValuEngine lowered shares of Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th.

Shares of Antares Pharma (NASDAQ ATRS) opened at $2.29 on Friday. Antares Pharma has a twelve month low of $1.58 and a twelve month high of $4.09. The firm has a market cap of $358.17, a PE ratio of -20.82 and a beta of 0.25. The company has a current ratio of 3.34, a quick ratio of 2.89 and a debt-to-equity ratio of 0.69.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The company had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.01 million. The business’s revenue was up 11.9% compared to the same quarter last year. equities analysts forecast that Antares Pharma will post -0.11 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Capital Advantage Inc. purchased a new position in Antares Pharma during the 3rd quarter valued at about $110,000. Alliancebernstein L.P. purchased a new position in Antares Pharma during the 2nd quarter valued at about $119,000. Legal & General Group Plc purchased a new position in Antares Pharma during the 2nd quarter valued at about $120,000. MML Investors Services LLC increased its position in Antares Pharma by 228.2% during the 2nd quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock valued at $139,000 after purchasing an additional 30,000 shares during the period. Finally, First Eagle Investment Management LLC increased its position in Antares Pharma by 150.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock valued at $162,000 after purchasing an additional 30,000 shares during the period. 34.63% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Antares Pharma, Inc. (ATRS) Given Consensus Recommendation of “Buy” by Analysts” was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/12/antares-pharma-inc-atrs-given-consensus-recommendation-of-buy-by-analysts.html.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.